TECHWIRE 30
(CIX: WRAL30)  1,062.45  up arrow+16.17  (1.55 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: Apple)  102.47  up arrow+2.71  (2.72 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: QUINTILES)  56.50  up arrow+1.72  (3.14 %)  Updated: 06:40 PM EDT, Oct 21 2014
(OP: BASF SE)  89.01  up arrow+1.55  (1.77 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: BioCryst)  11.37  down arrow-0.23  (-1.98 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: BioDelivery)  16.35  down arrow-0.39  (-2.33 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: CEMP)  12.19  down arrow-0.03  (-0.25 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: Cisco Systems)  23.51  up arrow+0.58  (2.53 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: Cree)  33.15  up arrow+0.25  (0.76 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: DARA)  0.87  up arrow+0.01  (1.17 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: EMC CORPORATION)  27.20  up arrow+0.25  (0.93 %)  Updated: 06:40 PM EDT, Oct 21 2014
(NQ: Extreme Networks)  3.20  up arrow+0.04  (1.27 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: FB)  78.69  up arrow+1.74  (2.26 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: GLAXOSMITHKLINE)  43.63  up arrow+0.02  (0.05 %)  Updated: 06:40 PM EDT, Oct 21 2014
(NQ: GOOG)  526.54  up arrow+5.7  (1.09 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: IBM)  163.23  down arrow-5.87  (-3.47 %)  Updated: 06:40 PM EDT, Oct 21 2014
(NY: LH)  101.30  up arrow+2.36  (2.39 %)  Updated: 06:40 PM EDT, Oct 21 2014
(OP: Lenovo Group)  29.02  up arrow+0.49  (1.72 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: MRK)  55.13  up arrow+1.08  (2 %)  Updated: 06:40 PM EDT, Oct 21 2014
(NQ: Microsoft Corp)  44.88  up arrow+0.8  (1.81 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: NTAP)  39.27  up arrow+0.73  (1.89 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: NOVARTIS AG)  88.61  up arrow+0.71  (0.81 %)  Updated: 06:40 PM EDT, Oct 21 2014
(OP: Novozymes A/S)  41.08  up arrow+0.7  (1.72 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: PFIZER)  28.28  up arrow+0.35  (1.25 %)  Updated: 06:40 PM EDT, Oct 21 2014
(NQ: Pozen)  8.27  up arrow+0.19  (2.35 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: RED HAT)  57.13  up arrow+0.79  (1.4 %)  Updated: 06:40 PM EDT, Oct 21 2014
(NQ: BBRY)  10.15  down arrow-0.15  (-1.46 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: Salix)  140.55  down arrow-1.44  (-1.01 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NQ: SQI)  15.33  up arrow+0.24  (1.59 %)  Updated: 08:10 PM EDT, Oct 21 2014

Posts tagged “Duke”

Updated February 20

Premium Lock NC Next Generation Network welcomes Google news but pushes ahead with own agenda

The people spearheading the NCNGN project are pushing ahead with their own plans even as they welcome the news that a Google Fiber network could be headed to the Triangle. "This is great news for the region, but this is still preliminary and our efforts are still continuing," said Elise Kohn

Service area as spelled out for NC NGN in RFP Service area as spelled out for NC NGN in RFP

February 19

Premium Lock Duke Health chief to head Institute of Medicine

Duke Health Dr. Victor Dzau, who serves as president and chief executive of Duke University Health System, has been named as the next president of the Institute of Medicine, which plays a lead role in advising Congress on health matters.

Updated January 20

Premium Lock Duke prof awarded $500K for osteoarthritis research

Arthritis  Dr. Farshid Guilak will use the Arthritis Foundation grant to research new drugs and stem cell therapies for osteoarthritis over the next five years at Duke University's School of Medicine.

Updated December 31, 2013

Premium Lock Argos files for $60M IPO to finance cancer immunotherapy trial

Nearly two years after pulling back on IPO plans, Argos Therapeutics is again seeking to go public to finance phase III clinical trials for its kidney cancer immunotherapy. Read more about Argos' plans.

Argos' immunotherapy process Argos' immunotherapy process

December 11, 2013

Premium Lock Oxygen Bio picks DCRI for late-stage clinical trial on heart drug

Oxygen Biotherapeutics Oxygen Biotherapeutics is prepping to start late-stage clinical trials on a drug candidate that could treat low cardiac outpput syndrome and the company is tapping the cardiac surgery trials experience of the Duke Clinical Research Institute to do it.

Updated December 10, 2013

Premium Lock Duke lands $2.9M Gates grant for HIV vaccine project

HIV AIDS research The Bill & Melinda Gates Foundation is backing a three-year effort at Duke University to develop a vaccine to combat HIV. The vaccine candidate mimics a virus particle.

Updated November 19, 2013

Premium Lock 'Hack Duke' - an 'off the charts' event for tech creators

Organized just this semester, the weekend event draws student inventors from across the southeast. Top prize goes to a team that turns sign language into speech through use of an amazing glove. Duke senior Dennis Li helped put the event together, and Adam Klein of The American Underground gives the tech showcase a big thumbs up.

October 30, 2013

Premium Lock Aerie Pharma closes IPO, raising $68.4M

Aerie Pharmaceuticals Glaucoma drug developer Aerie Pharmaceuticals (NASDAQ:AERI) closed its initial public offering of stock Wednesday raising a total of $68.4 million that the company plans to use for clinical trials.

Updated October 25, 2013

Premium Lock Aerie Pharma cuts stock price, adds shares for $67M IPO; Chimerix sells more stock

Aerie Pharmaceuticals Aerie Pharmaceuticals' $67 million IPO was priced at $10 per share, well below the $12 to $14 per share range the company had previously set. Read more about the offering.

September 27, 2013

Premium Lock Regado Biosciences cutting jobs at Durham operation

Regado's pipeline The drug development firm, which is built around technology developed at Duke University and recently went public, is cutting jobs to save cash.

September 13, 2013

Premium Lock UNC awarded $5.8M to lead research project on cloud cybersecurity

UNC is leading four other institutions in conducting cybersecurity in cloud computing. Read more about the federally funded research project.

Network security  Network security

Updated September 4, 2013

Premium Lock Duke's Dan Ariely cracks Bloomberg's 'Most Influential' list

What does best-selling author and Duke professor Dan Ariely have in common with some of the best-known names in business, economics and government? He's on the latest "50 Most Influential" list from Bloomberg Markets Magazine.

Dan Ariely's latest book Dan Ariely's latest book

Updated August 30, 2013

Premium Lock Social media spending is up but showing results proves to be a tough cookie

Corporations wants to jump onto the social media bandwagon. But companies so far have yet to see much bang for their buck, according to a survey of marketing executives conducted by Duke University.

How companies view the impact of social media How companies view the impact of social media

Updated August 28, 2013

Premium Lock NC's Next Generation Network project targets fall 2014 for rollout

The organizers of the North Carolina Next Generation Network project are wading through a larger than expected response from a variety of partnerships and firms that want to help build an ultra-high speed Internet project across the Triangle and Triad. The NCNGN project manager says the timeline for picking the builders is "fluid" but backers "hope the service will begin by the fourth quarter 2014." The full story is available to WRALTechWire Insiders

Service area as spelled out for NC NGN in RFP Service area as spelled out for NC NGN in RFP

Updated August 23, 2013

Premium Lock Biotech Center gives COIN $350,000 transfusion, kickstarts 9 ventures

Biotech & Life Science The Center of Innovation for Nanobiotechnology, better known as COIN, is giving an extended lease on life, and a host of startups land seed capital for growth in what could be the largest N.C. Biotech Center grants the state will see for a long while due to budget cuts.

Updated August 23, 2013

Premium Lock Regado Biosciences shows some 'pop' on IPO day

Shares in Regado Biosciences show some significant appeal to investors on IPO day, jumping more than 30 percent at one point before fading. The company is commercializing technology developed at Duke University.

Regado's pipeline Regado's pipeline

August 22, 2013

Premium Lock Duke spinout Regado Biosciences goes public - but for less cash that hoped

Regado The life science company, which has licensed technology from Duke University, had hoped to raise as much as $80.

July 29, 2013

Premium Lock Duke Institute for Health Innovation launches to connect clinicians, companies

A new Duke University institute intended to foster innovation from Duke Health is having its coming out party. Read how the institute plans to bring new ideas to health care.

Tom Kaminski, Duke Institute for Health Innovation Tom Kaminski, Duke Institute for Health Innovation

July 22, 2013

Premium Lock Duke study: Fish oil derivative could ease neuropathic pain

A compound derived from fish oil showed the ability to reduce pain in a Duke University study, suggesting it could be developed into an alternative to addictive opioid pain meds.

Duke University research on pain treatments Duke University research on pain treatments

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Scroll